ATyr Pharma, Company Insiders
| ATYR Stock | 3.44 0.15 4.56% |
ATyr Pharma,'s insiders are aggressively buying. The analysis of the overall insider sentiment regarding aTyr Pharma, suggests that virtually all insiders are extremely bullish. ATyr Pharma, employs about 56 people. The company is managed by 13 executives with a total tenure of roughly 131 years, averaging almost 10.0 years of service per executive, having 4.31 employees per reported executive.
ATyr Pharma,'s Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-07-24 | Paul Schimmel | Acquired 52300 @ 1.93 | View | ||
| 2024-07-22 | Paul Schimmel | Acquired 41052 @ 1.74 | View |
Monitoring ATyr Pharma,'s insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
ATyr |
ATyr Pharma, Management Team Effectiveness
The company has return on total asset (ROA) of (0.3274) % which means that it has lost $0.3274 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6176) %, meaning that it created substantial loss on money invested by shareholders. ATyr Pharma,'s management efficiency ratios could be used to measure how well ATyr Pharma, manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/28/2024, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.55. At this time, ATyr Pharma,'s Other Current Assets are relatively stable compared to the past year. As of 11/28/2024, Non Currrent Assets Other is likely to grow to about 139 K, while Total Assets are likely to drop slightly above 101.9 M.As of 11/28/2024, Common Stock Shares Outstanding is likely to drop to about 30.3 M
ATyr Pharma, Workforce Comparison
aTyr Pharma, is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 190,812. ATyr Pharma, adds roughly 56.0 in number of employees claiming only tiny portion of equities under Health Care industry.
ATyr Pharma, Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ATyr Pharma, insiders, such as employees or executives, is commonly permitted as long as it does not rely on ATyr Pharma,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ATyr Pharma, insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Schimmel Paul over three months ago Acquisition by Schimmel Paul of 52300 shares of ATyr Pharma, at 1.9319 subject to Rule 16b-3 |
ATyr Pharma, Notable Stakeholders
An ATyr Pharma, stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ATyr Pharma, often face trade-offs trying to please all of them. ATyr Pharma,'s stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ATyr Pharma,'s stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| XiangLei Yang | Founder | Profile | |
| MS MD | CEO President | Profile | |
| Ashlee Dunston | Director Communications | Profile | |
| Danielle Campbell | VP Resource | Profile | |
| Jill CPA | Chief Officer | Profile | |
| Jill Broadfoot | Chief Officer | Profile | |
| Jayant MBA | Vice Operations | Profile | |
| Peter Villiger | Vice Development | Profile | |
| Nancy Krueger | General Secretary | Profile | |
| Ying Buechler | Executive Manufacturing | Profile | |
| David King | Scientific Consultant | Profile | |
| Nancy JD | General Secretary | Profile | |
| Leslie Nangle | Vice Research | Profile |
About ATyr Pharma, Management Performance
The success or failure of an entity such as aTyr Pharma, often depends on how effective the management is. ATyr Pharma, management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ATyr management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ATyr management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.53) | (0.55) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.56) | (0.58) |
ATyr Pharma, Workforce Analysis
Traditionally, organizations such as ATyr Pharma, use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ATyr Pharma, within its industry.ATyr Pharma, Manpower Efficiency
Return on ATyr Pharma, Manpower
| Revenue Per Employee | 6.3K | |
| Revenue Per Executive | 27.2K | |
| Net Loss Per Employee | 899.8K | |
| Net Loss Per Executive | 3.9M | |
| Working Capital Per Employee | 1.5M | |
| Working Capital Per Executive | 6.7M |
Additional Tools for ATyr Stock Analysis
When running ATyr Pharma,'s price analysis, check to measure ATyr Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma, is operating at the current time. Most of ATyr Pharma,'s value examination focuses on studying past and present price action to predict the probability of ATyr Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma,'s price. Additionally, you may evaluate how the addition of ATyr Pharma, to your portfolios can decrease your overall portfolio volatility.